Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 NCoV-19 and BNT162b2 MRNA Vaccines

Overview

Journal Vaccines (Basel)

Date 2022 Mar 26

PMID 35334989

Authors

Ulrika Marking

Sebastian Havervall

Nina Greilert-Norin

Henry Ng

Kim Blom

Peter Nilsson

Mia Phillipson

Sophia Hober

Charlotta Nilsson

Sara Mangsbo

Wanda Christ

Jonas Klingstrom

Max Gordon

Mikael Aberg

Charlotte Thalin

Affiliations

Soon will be listed here.

Abstract

Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens. To evaluate duration of immune responses after primary vaccination with homologous adeno-vectored ChAdOx1 nCoV-19 vaccine (ChAd) or heterologous ChAd/BNT162b2 mRNA vaccine (BNT), anti-spike-IgG and SARS-CoV-2 VOC-neutralizing antibody responses were measured in 354 healthcare workers (HCW) at 2 weeks, 3 months, 5 months and 6 months after the second vaccine dose. T-cell responses were investigated using a whole blood interferon gamma (IFN-γ) release assay 2 weeks and 3 months post second vaccine dose. Two hundred and ten HCW immunized with homologous BNT were enrolled for comparison of antibody responses. In study participants naïve to SARS-CoV-2 prior to vaccination, heterologous ChAd/BNT resulted in 6-fold higher peak anti-spike IgG antibody titers compared to homologous ChAd vaccination. The half-life of antibody titers was 3.1 months (95% CI 2.8-3.6) following homologous ChAd vaccination and 1.9 months (95% CI 1.7-2.1) after heterologous vaccination, reducing the GMT difference between the groups to 3-fold 6 months post vaccination. Peak T-cell responses were stronger in ChAd/BNT vaccinees, but no significant difference was observed 3 months post vaccination. SARS-CoV-2 infection prior to vaccination resulted in substantially higher peak GMTs and IFN-γ levels and enhanced SARS-CoV-2 specific antibody and T cell responses over time. Heterologous primary SARS-CoV-2 immunization with ChAd and BNT elicits a stronger initial immune response compared to homologous vaccination with ChAd. However, although the differences in humoral responses remain over 6 months, the difference in SARS-CoV-2 specific T cell responses are no longer significant three months after vaccination.

Citing Articles

Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine.

Valiate B, Castro J, Marcal T, Andrade L, Oliveira L, Maia G iScience. 2024; 27(7):110177.

PMID: 38993669 PMC: 11238127. DOI: 10.1016/j.isci.2024.110177.

Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.

Bladh O, Aguilera K, Marking U, Kihlgren M, Greilert Norin N, Smed-Sorensen A Front Immunol. 2024; 15:1346749.

PMID: 38558811 PMC: 10978617. DOI: 10.3389/fimmu.2024.1346749.

Differences in BNT126b2 and ChAdOx1 Homologous Vaccination Antibody Response among Teachers in Poznan, Poland.

Lorent D, Nowak R, Jankowska M, Kuszel L, Zmora P Vaccines (Basel). 2023; 11(1).

PMID: 36679962 PMC: 9862687. DOI: 10.3390/vaccines11010118.

Humoral and cellular immune response after severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid vaccination in heart transplant recipients: An observational study in France.

Casenaz A, Grosjean S, Aho-Glele L, Bour J, Auvray C, Manoha C Front Med (Lausanne). 2022; 9:1027708.

PMID: 36388890 PMC: 9643719. DOI: 10.3389/fmed.2022.1027708.

Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19.

Kim D, Lee S, Park S, Kim P, Lee S, Lee N Vaccines (Basel). 2022; 10(11).

PMID: 36366372 PMC: 9692595. DOI: 10.3390/vaccines10111864.

References

Hillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C . Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. 2021; 9(11):1255-1265. PMC: 8360702. DOI: 10.1016/S2213-2600(21)00357-X. View

Mangsbo S, Havervall S, Lauren I, Lindsay R, Falk A, Marking U . An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses. PLoS One. 2021; 16(9):e0258041. PMC: 8483319. DOI: 10.1371/journal.pone.0258041. View

Rudberg A, Havervall S, Manberg A, Falk A, Aguilera K, Ng H . SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat Commun. 2020; 11(1):5064. PMC: 7544689. DOI: 10.1038/s41467-020-18848-0. View

Tenbusch M, Schumacher S, Vogel E, Priller A, Held J, Steininger P . Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis. 2021; 21(9):1212-1213. PMC: 8321428. DOI: 10.1016/S1473-3099(21)00420-5. View

Pozzetto B, Legros V, Djebali S, Barateau V, Guibert N, Villard M . Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature. 2021; 600(7890):701-706. DOI: 10.1038/s41586-021-04120-y. View

Martinez-Baz I, Trobajo-Sanmartin C, Miqueleiz A, Guevara M, Fernandez-Huerta M, Burgui C . Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Euro Surveill. 2021; 26(39). PMC: 8485582. DOI: 10.2807/1560-7917.ES.2021.26.39.2100894. View

Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S . Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021; 27(9):1530-1535. PMC: 8440177. DOI: 10.1038/s41591-021-01464-w. View

Rossler A, Riepler L, Bante D, von Laer D, Kimpel J . SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med. 2022; 386(7):698-700. PMC: 8781314. DOI: 10.1056/NEJMc2119236. View

Vallee A, Vasse M, Mazaux L, Bonan B, Amiel C, Zia-Chahabi S . An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines. J Clin Med. 2021; 10(17). PMC: 8432244. DOI: 10.3390/jcm10173817. View

10.

Nordstrom P, Ballin M, Nordstrom A . Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022; 399(10327):814-823. PMC: 8816388. DOI: 10.1016/S0140-6736(22)00089-7. View

11.

Shaw R, Stuart A, Greenland M, Liu X, Nguyen Van-Tam J, Snape M . Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet. 2021; 397(10289):2043-2046. PMC: 8115940. DOI: 10.1016/S0140-6736(21)01115-6. View

12.

Powell A, Power L, Westrop S, McOwat K, Campbell H, Simmons R . Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England. Euro Surveill. 2021; 26(28). PMC: 8284043. DOI: 10.2807/1560-7917.ES.2021.26.28.2100634. View

13.

Greinacher A, Thiele T, Warkentin T, Weisser K, Kyrle P, Eichinger S . Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021; 384(22):2092-2101. PMC: 8095372. DOI: 10.1056/NEJMoa2104840. View

14.

Varnaite R, Garcia M, Glans H, Maleki K, Sandberg J, Tynell J . Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients. J Immunol. 2020; 205(9):2437-2446. PMC: 7576114. DOI: 10.4049/jimmunol.2000717. View

15.

Barros-Martins J, Hammerschmidt S, Cossmann A, Odak I, Stankov M, Ramos G . Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021; 27(9):1525-1529. PMC: 8440184. DOI: 10.1038/s41591-021-01449-9. View

16.

Chiu N, Chi H, Tu Y, Huang Y, Tai Y, Weng S . To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination. Expert Rev Vaccines. 2021; 20(10):1211-1220. PMC: 8425437. DOI: 10.1080/14760584.2021.1971522. View

17.

Benning L, Tollner M, Hidmark A, Schaier M, Nusshag C, Kalble F . Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines (Basel). 2021; 9(8). PMC: 8402499. DOI: 10.3390/vaccines9080857. View

18.

Poukka E, Baum U, Palmu A, Lehtonen T, Salo H, Nohynek H . Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. Vaccine. 2021; 40(5):701-705. PMC: 8683266. DOI: 10.1016/j.vaccine.2021.12.032. View

19.

Havervall S, Ng H, Falk A, Greilert-Norin N, Manberg A, Marking U . Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. J Intern Med. 2021; 291(1):72-80. PMC: 8661920. DOI: 10.1111/joim.13387. View

20.

Ho T, Chen Y, Chan H, Chang C, Chuang K, Lee C . The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2. Vaccines (Basel). 2021; 9(10). PMC: 8537265. DOI: 10.3390/vaccines9101163. View